Previous 10 | Next 10 |
home / stock / mdgef / mdgef news
MARTINSRIED and MUNICH, Germany, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announced today the appointment of Pamela Kec...
Milestone payment is related to the establishment of 2seventy bio’s strategic partnership with JW Therapeutics Payment provides further validation of Medigene’s end-to-end platform MARTINSRIED, Germany and MUNICH, Germany, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Martinsried ...
The following slide deck was published by Medigene AG in conjunction with their 2022 Q2 earnings call. For further details see: Medigene AG 2022 Q2 - Results - Earnings Call Presentation
Medigene AG (MDGEF) H1 2022 Earnings Conference Call August 03, 2022, 09:00 AM ET Company Participants Anna Niedl - Investor Relations Dolores Schendel - Chief Scientific Officer Birger Kohlert - Chief Financial Officer Conference Call Participants Xi...
The following slide deck was published by Medigene AG in conjunction with this event. For further details see: MediGene (MDGEF ) Investor Presentation - Slideshow
Medigene AG (MDGEF) Annual Report 2020 Conference Call March 25, 2021 10:00 AM ET Company Participants Anna Niedl – Investor Relations Dolores Schendel – Chief Executive Officer and Chief Scientific Officer Axel Malkomes – Chief Financial Officer and Chief Business Develo...
The following slide deck was published by Medigene AG in conjunction with their 2020 Q4 earnings call. For further details see: Medigene AG 2020 Q4 - Results - Earnings Call Presentation
Medigene AG (MDGEF): FY GAAP EPS of -€1.18.Revenue of €8.75M (-18% Y/Y)Press Release For further details see: Medigene AG reports FY 2020 results
Clinical stage immuno-oncology company Medigene AG ([[MDGEF]]) announces the discontinuation of its blood cancer treatment MDG1021's development program, as it looks to focus on the development of T cell immunotherapies.Recruitment for the Phase I clinical trial of MDG1021 dire...
The following slide deck was published by Medigene AG in conjunction with this Read more ...
News, Short Squeeze, Breakout and More Instantly...
Planegg/Martinsried, July 23, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today announced the presentation of two posters...
Planegg/Martinsried, July 3, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announces today that the Company has been issued...
Planegg/Martinsried, June 27, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today provides a detailed overview of its lead ...